Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pan-MSI-ACSE: first-line dostarlimab versus standard chemotherapy in dMMR/MSI-H non-colorectal/non-endometrial advanced cancers
2023-505298-34-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dostarlimab in Nonhematologic neoplasms, small bowel adenocarcinoma (SBA), gastric adenocarcinoma and 8 more (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival. Planned start Jul 2024; status: authorised.
02
Drugs
dostarlimab
03
Conditions
Nonhematologic neoplasmssmall bowel adenocarcinoma (SBA)gastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2023-505298-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505298-34-00.